Free Trial
OTCMKTS:PHMMF

Pharma Mar (PHMMF) Stock Price, News & Analysis

Pharma Mar logo
$75.00 0.00 (0.00%)
(As of 11/22/2024 ET)

About Pharma Mar Stock (OTCMKTS:PHMMF)

Key Stats

Today's Range
$75.00
$75.00
50-Day Range
$45.85
$75.00
52-Week Range
$26.85
$75.00
Volume
N/A
Average Volume
10 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Pharma Mar Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
1st Percentile Overall Score

PHMMF MarketRank™: 

Pharma Mar scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Book Value per Share Ratio

    Pharma Mar has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Pharma Mar has a short interest ratio ("days to cover") of 266, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pharma Mar has recently increased by 116.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pharma Mar does not currently pay a dividend.

  • Dividend Growth

    Pharma Mar does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Pharma Mar has a short interest ratio ("days to cover") of 266, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pharma Mar has recently increased by 116.26%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pharma Mar has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pharma Mar this week, compared to 0 articles on an average week.
Receive PHMMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter.

PHMMF Stock News Headlines

Pharma Mar S.A. Reduces Share Capital by Canceling Shares
Pharma Mar Achieves Legal Win in Aplidin Case
Free Ebook shares Tesla’s roadmap to $500 a share
Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.
PHMMF Pharma Mar, S.A.
See More Headlines

PHMMF Stock Analysis - Frequently Asked Questions

Pharma Mar's stock was trading at $46.26 on January 1st, 2024. Since then, PHMMF stock has increased by 62.1% and is now trading at $75.00.
View the best growth stocks for 2024 here
.

Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:PHMMF
Previous Symbol
NASDAQ:PHMMF
CIK
N/A
Employees
509
Year Founded
1986

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$171.15 million
Cash Flow
$0.41 per share
Book Value
$11.62 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.41

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (OTCMKTS:PHMMF) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners